BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tapper EB, Halbert B, Mellinger J. Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study. Clin Gastroenterol Hepatol. 2016;14:1181-1188.e2. [PMID: 27085758 DOI: 10.1016/j.cgh.2016.04.009] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Tapper EB, Korovaichuk S, Baki J, Williams S, Nikirk S, Waljee AK, Parikh ND. Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era. Clin Gastroenterol Hepatol 2021;19:604-606.e1. [PMID: 31887447 DOI: 10.1016/j.cgh.2019.12.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
2 Rosenblatt R, Cohen-mekelburg S, Shen N, Tafesh Z, Lucero C, Kumar S, Fortune B, Liu SY, Brown R, Jesudian A. Cirrhosis as a Comorbidity in Conditions Subject to the Hospital Readmissions Reduction Program. Am J Gastroenterol 2019;114:1488-95. [DOI: 10.14309/ajg.0000000000000257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hu C, Anjur V, Saboo K, Reddy KR, O'leary J, Tandon P, Wong F, Garcia-tsao G, Kamath PS, Lai JC, Biggins SW, Fallon MB, Thuluvath P, Subramanian RM, Maliakkal B, Vargas H, Thacker LR, Iyer RK, Bajaj JS. Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. Am J Gastroenterol 2021;116:336-46. [DOI: 10.14309/ajg.0000000000000971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World J Gastroenterol 2017; 23(37): 6868-6876 [PMID: 29085229 DOI: 10.3748/wjg.v23.i37.6868] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
5 Thomson MJ, Lok AS, Tapper EB. Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes. Liver Int 2018;38:1882-90. [PMID: 29845749 DOI: 10.1111/liv.13892] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
6 Chirapongsathorn S, Krittanawong C, Enders FT, Pendegraft R, Mara KC, Borah BJ, Visscher SL, Loftus CG, Shah VH, Talwalkar JA, Kamath PS. Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. Hepatol Commun. 2018;2:188-198. [PMID: 29404526 DOI: 10.1002/hep4.1137] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
7 Acharya C, Sehrawat TS, McGuire DB, Shaw J, Fagan A, McGeorge S, Olofson A, White MB, Gavis E, Kamath PS, Bergstrom L, Bajaj JS. Perspectives of Inpatients With Cirrhosis and Caregivers on Using Health Information Technology: Cross-sectional Multicenter Study. J Med Internet Res 2021;23:e24639. [PMID: 33744844 DOI: 10.2196/24639] [Reference Citation Analysis]
8 Aday A, O'Leary JG. Acute on Chronic Liver Failure: Definition and Implications. Clin Liver Dis 2020;24:521-34. [PMID: 32620286 DOI: 10.1016/j.cld.2020.04.004] [Reference Citation Analysis]
9 Orman ES, Ghabril M, Emmett TW, Chalasani N. Hospital Readmissions in Patients with Cirrhosis: A Systematic Review. J Hosp Med. 2018;. [PMID: 29694458 DOI: 10.12788/jhm.2967] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
10 Ganapathy D, Acharya C, Lachar J, Patidar K, Sterling RK, White MB, Ignudo C, Bommidi S, DeSoto J, Thacker LR, Matherly S, Shaw J, Siddiqui MS, Puri P, Sanyal AJ, Luketic V, Lee H, Stravitz RT, Bajaj JS. The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. Liver Int. 2017;37:1843-1851. [PMID: 28618192 DOI: 10.1111/liv.13494] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
11 Tapper EB, Essien UR, Zhao Z, Ufere NN, Parikh ND. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. J Hepatol 2022:S0168-8278(22)00116-7. [PMID: 35367057 DOI: 10.1016/j.jhep.2022.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rosenblatt R, Shen N, Tafesh Z, Cohen‐mekelburg S, Crawford CV, Kumar S, Lucero C, Brown RS, Jesudian A, Fortune BE. The North American Consortium for the Study of End‐Stage Liver Disease–Acute‐on‐Chronic Liver Failure Score Accurately Predicts Survival: An External Validation Using a National Cohort. Liver Transpl 2019;26:187-95. [DOI: 10.1002/lt.25696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
13 Sood KT, Wong RJ. Hepatic Encephalopathy is a Strong Predictor of Early Hospital Readmission Among Cirrhosis Patients. J Clin Exp Hepatol 2019;9:484-90. [PMID: 31571775 DOI: 10.1016/j.jceh.2019.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Rush B, Deol N, Teriyaki A, Sey M, Jairath V, Walley KR, Celi LA, Brahmania M. Lower 90-day Hospital Readmission Rates for Esophageal Variceal Bleeding After TIPS: A Nationwide Linked Analysis. J Clin Gastroenterol 2020;54:90-5. [PMID: 30829905 DOI: 10.1097/MCG.0000000000001199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. Hepatol Commun 2019;3:1510-9. [PMID: 31701074 DOI: 10.1002/hep4.1425] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
16 Bloom PP, Ventoso M, Tapper E, Ha J, Richter JM. A Telemonitoring Intervention for Cirrhotic Ascites Management Is Cost-Saving. Dig Dis Sci 2021. [PMID: 34018070 DOI: 10.1007/s10620-021-07013-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
17 Shaheen AA, Swain MG. Letter to Editor: Using Proper Methods to Identify Patients With Cirrhosis in Administrative Databases Is Crucial to Correctly Predict Outcomes. Hepatology 2019;69:2301-2. [PMID: 30383299 DOI: 10.1002/hep.30343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018;11:1756284818800307. [PMID: 30283499 DOI: 10.1177/1756284818800307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Aspinall RJ. Reducing recurrent hospital admissions in patients with decompensated cirrhosis. Br J Hosp Med (Lond) 2018;79:93-6. [PMID: 29431486 DOI: 10.12968/hmed.2018.79.2.93] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. Clin Liver Dis 2019;23:607-23. [PMID: 31563214 DOI: 10.1016/j.cld.2019.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
22 Bloom PP, Marx M, Wang TJ, Green B, Ha J, Bay C, Chung RT, Richter JM. Attitudes towards digital health tools for outpatient cirrhosis management in patients with decompensated cirrhosis. BMJ Innov 2020;6:18-25. [DOI: 10.1136/bmjinnov-2019-000369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
23 Çelik F, Bektaş H. Preventive and Treatment Interventions for Abdominal Ascites of Patients with Liver Cirrhosis: A Systematic Review of Randomized Controlled Trials. Florence Nightingale J Nurs 2021;29:250-62. [PMID: 34263244 DOI: 10.5152/FNJN.2021.19171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Baki JA, Tapper EB. Contemporary Epidemiology of Cirrhosis. Curr Treat Options Gastroenterol 2019;17:244-53. [PMID: 30949926 DOI: 10.1007/s11938-019-00228-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AM, Pate V, Barnes EL, Schlusser CL, Baron TH, Shaheen NJ, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology 2021:S0016-5085(21)03655-6. [PMID: 34678215 DOI: 10.1053/j.gastro.2021.10.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
26 Neff G, Zachry W III. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. Pharmacoeconomics 2018;36:809-22. [PMID: 29651649 DOI: 10.1007/s40273-018-0641-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
27 Tapper EB, Baki J, Hummel S, Lok A. Design and rationale of a randomized-controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial. Gastroenterol Rep (Oxf) 2019;7:146-9. [PMID: 30976428 DOI: 10.1093/gastro/goz005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Spiewak T, Taefi A, Patel S, Li CS, Chak E. Racial disparities of Black Americans hospitalized for decompensated liver cirrhosis. BMC Gastroenterol. 2020;20:245. [PMID: 32727386 DOI: 10.1186/s12876-020-01392-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Cheema E, Al-Aryan A, Al-Hamid A. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. Eur J Clin Pharmacol 2019;75:1047-58. [PMID: 31079169 DOI: 10.1007/s00228-019-02688-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
30 Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One 2017;12:e0182900. [PMID: 28837634 DOI: 10.1371/journal.pone.0182900] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 5.6] [Reference Citation Analysis]
31 Sahney A, Wadhawan M. Encephalopathy in Cirrhosis: Prevention and Management. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.12.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Garg SK, Goyal H, Obaitan I, Shah PA, Sarvepalli S, Jophlin LL, Singh D, Asrani S, Kamath PS, Leise MD. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database. Ann Transl Med 2021;9:1052. [PMID: 34422964 DOI: 10.21037/atm-20-1762] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Rosenblatt R, Atteberry P, Tafesh Z, Ravikumar A, Crawford CV, Lucero C, Jesudian AB, Brown RS Jr, Kumar S, Fortune BE. Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. Dig Liver Dis 2021;53:445-51. [PMID: 33153928 DOI: 10.1016/j.dld.2020.10.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE Jr. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021;298:493-504. [PMID: 33497318 DOI: 10.1148/radiol.2021201960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Yazdanyar A, Lo KB, Pelayo J, Sanon J, Romero A, Quintero E, Ahluwalia A, Gupta S, Sankaranarayanan R, Mathew R, Rangaswami J. Association Between Cirrhosis and 30-Day Rehospitalization After Index Hospitalization for Heart Failure. Curr Probl Cardiol 2021;:100993. [PMID: 34571101 DOI: 10.1016/j.cpcardiol.2021.100993] [Reference Citation Analysis]
36 Morales BP, Planas R, Bartoli R, Morillas RM, Sala M, Casas I, Armengol C, Masnou H. HEPACONTROL. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis. Dig Liver Dis. 2018;50:76-83. [PMID: 28870446 DOI: 10.1016/j.dld.2017.08.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
37 Luo M, Mu R, Liu JF, Bai FH. Novel computerized psychometric tests as primary screening tools for the diagnosis of minimal hepatic encephalopathy. World J Clin Cases 2020; 8(16): 3377-3389 [PMID: 32913845 DOI: 10.12998/wjcc.v8.i16.3377] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Shaheen AA, Nguyen HH, Congly SE, Kaplan GG, Swain MG. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019;39:878-884. [PMID: 30688401 DOI: 10.1111/liv.14054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
39 Trivedi HD, Tapper EB. Interventions to improve physical function and prevent adverse events in cirrhosis. Gastroenterol Rep (Oxf) 2018;6:13-20. [PMID: 29479438 DOI: 10.1093/gastro/gox042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
40 Mumtaz K, Issak A, Porter K, Kelly S, Hanje J, Michaels AJ, Conteh LF, El-Hinnawi A, Black SM, Abougergi MS. Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic Patients: A Model Based on the Administrative Database. Hepatology 2019;70:630-9. [PMID: 30218583 DOI: 10.1002/hep.30274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
41 Tapper EB. A Trial of Ornithine Phenylacetate and the Arc of Ammonia's History in the Management of Overt Hepatic Encephalopathy. Clin Gastroenterol Hepatol 2021;19:2493-5. [PMID: 33157316 DOI: 10.1016/j.cgh.2020.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy and Nutrition Influences: A Narrative Review. Nutr Clin Pract 2020;35:36-48. [PMID: 31872484 DOI: 10.1002/ncp.10458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther 2019;49:1518-27. [PMID: 31032966 DOI: 10.1111/apt.15265] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
44 Wigg AJ, Chin JK, Muller KR, Ramachandran J, Woodman RJ, Kaambwa B. Cost-effectiveness of a chronic disease management model for cirrhosis: Analysis of a randomized controlled trial. J Gastroenterol Hepatol. 2018;:. [PMID: 29462834 DOI: 10.1111/jgh.14127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zou B, Yeo YH, Jeong D, Sheen E, Park H, Nguyen P, Hsu YC, Garcia G, Nguyen MH. Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. Sci Rep 2018;8:9969. [PMID: 29967363 DOI: 10.1038/s41598-018-28317-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
46 Rubin JN, Shoag D, Gaetano JN, Micic D, Sengupta N. Risk Factors for 30-day Hospital Readmission for Diverticular Hemorrhage. Journal of Clinical Gastroenterology 2019;53:e133-41. [DOI: 10.1097/mcg.0000000000000883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Salman T, Elsabaawy M, Omar M, Afify M, Elezawy H, Ghanem S, Abdelraouf O, Rewisha E, Shebl N. Evaluation of different diagnostic modalities of minimal hepatic encephalopathy in cirrhotic patients: case-control study. Clin Exp Hepatol 2021;7:312-9. [PMID: 34712834 DOI: 10.5114/ceh.2021.109292] [Reference Citation Analysis]
48 Carbonneau M, Davyduke T, Tandon P. Care Coordination in Cirrhosis. Curr Hepatology Rep 2018;17:33-41. [DOI: 10.1007/s11901-018-0388-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Tan J, Tang X, He Y, Xu X, Qiu D, Chen J, Zhang Q, Zhang L. In-patient Expenditure Between 2012 and 2020 Concerning Patients With Liver Cirrhosis in Chongqing: A Hospital-Based Multicenter Retrospective Study. Front Public Health 2022;10:780704. [PMID: 35350474 DOI: 10.3389/fpubh.2022.780704] [Reference Citation Analysis]
50 Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, Su GL. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology 2018;68:1498-507. [PMID: 29091289 DOI: 10.1002/hep.29628] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
51 Tocia C, Dumitru A, Alexandrescu L, Popescu R, Dumitru E. Timing of paracentesis and outcomes in hospitalized patients with decompensated cirrhosis. World J Hepatol 2020; 12(12): 1267-1275 [PMID: 33442453 DOI: 10.4254/wjh.v12.i12.1267] [Reference Citation Analysis]
52 Wei M, Ford J, Li Q, Jeong D, Kwong AJ, Nguyen MH, Chang MS. Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California. Dig Dis Sci 2018;63:2267-74. [PMID: 29457210 DOI: 10.1007/s10620-018-4964-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
53 Tapper EB, Parikh ND, Waljee AK, Volk M, Carlozzi NE, Lok AS. Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. Am J Gastroenterol 2018;113:529-38. [PMID: 29533396 DOI: 10.1038/ajg.2018.6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
54 Rosenblatt R, Tafesh Z, Shen N, Cohen-mekelburg S, Kumar S, Lucero C, Brown RS, Verna E, Fortune B, Jesudian A. Early Paracentesis in High-Risk Hospitalized Patients: Time for a New Quality Indicator. Am J Gastroenterol 2019;114:1863-9. [DOI: 10.14309/ajg.0000000000000443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Hudson B, Round J, Georgeson B, Pring A, Forbes K, Mccune CA, Verne J. Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England. The Lancet Gastroenterology & Hepatology 2018;3:95-103. [DOI: 10.1016/s2468-1253(17)30362-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 6.8] [Reference Citation Analysis]
56 Potnis A, VanMeter S, Stange J. Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States. Int J Hepatol 2021;2021:8542179. [PMID: 34211786 DOI: 10.1155/2021/8542179] [Reference Citation Analysis]
57 Chirapongsathorn S, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Phaosawasdi K, Treeprasertsuk S. Thirty-Day Readmission and Cost Analysis in Patients With Cirrhosis: A Nationwide Population-Based Data. Hepatol Commun 2020;4:453-60. [PMID: 32140661 DOI: 10.1002/hep4.1472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Asrani SK, Hall L, Hagan M, Sharma S, Yeramaneni S, Trotter J, Talwalkar J, Kanwal F. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol 2019;114:98-106. [PMID: 30333543 DOI: 10.1038/s41395-018-0365-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
59 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 221] [Cited by in F6Publishing: 179] [Article Influence: 73.7] [Reference Citation Analysis]
60 Bajaj JS, Kamath PS. The brain gets its say: Hepatic encephalopathy and its evolving role in transplant priority. Liver Transpl 2016;22:1319-20. [PMID: 27509240 DOI: 10.1002/lt.24521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
61 Louissaint J, Deutsch-link S, Tapper EB. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology 2022;20:S1-8. [DOI: 10.1016/j.cgh.2022.04.036] [Reference Citation Analysis]
62 Ampuero J, Gil A, Viloria MDM, Rico MC, Millán R, Camacho I, Romero‐gómez M. Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. Liver Int 2020;40:921-30. [DOI: 10.1111/liv.14297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Sobotka LA, Spitzer C, Hinton A, Michaels A, Hanje AJ, Mumtaz K, Conteh LF. Management of hepatic hydrothorax and effect on length of stay, mortality, cost, and 30-day hospital readmission. J Gastroenterol Hepatol 2020;35:641-7. [PMID: 31441096 DOI: 10.1111/jgh.14842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Poojary P, Saha A, Chauhan K, Simoes P, Sands BE, Cho J, Ullman T, Nadkarni G, Ungaro R. Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis 2017;23:347-56. [PMID: 28221246 DOI: 10.1097/MIB.0000000000001041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
65 Thomson M, Tapper EB. Towards patient-centred and cost-effective care for patients with cirrhosis and ascites. The Lancet Gastroenterology & Hepatology 2018;3:75-6. [DOI: 10.1016/s2468-1253(17)30339-4] [Reference Citation Analysis]
66 Garg SK, Sarvepalli S, Singh D, Obaitan I, Peeraphatdit T, Jophlin L, Asrani SK, Shah VH, Leise MD. Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis. Journal of Clinical Gastroenterology 2019;53:759-64. [DOI: 10.1097/mcg.0000000000001202] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
67 Fritsche MR, Watchmaker JM, Lipnik AJ, Baker JC, Geevarghese S, Banovac F, Omary RA, Brown DB. Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy. Journal of Vascular and Interventional Radiology 2018;29:550-5. [DOI: 10.1016/j.jvir.2017.11.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Patidar KR, Thacker LR, Wade JB, White MB, Gavis EA, Fagan A, Sterling RK, Fuchs M, Siddiqui MS, Matherly S, Stravitz RT, Sanyal AJ, Puri P, Luketic VA, Bajaj JS. Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis. Dig Dis Sci 2017;62:1173-9. [PMID: 28258378 DOI: 10.1007/s10620-017-4509-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
69 Henry Z. Readmissions for Cirrhosis Within the Healthcare Readmissions Reduction Program: A Hidden Challenge. Am J Gastroenterol 2019;114:1419-20. [PMID: 31449155 DOI: 10.14309/ajg.0000000000000368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Brahmania M, Wiskar K, Walley KR, Celi LA, Rush B. Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2021;36:1088-94. [PMID: 32562577 DOI: 10.1111/jgh.15153] [Reference Citation Analysis]
71 Tapper EB, Zhao L, Nikirk S, Baki J, Parikh ND, Lok AS, Waljee AK. Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. Am J Gastroenterol 2020;115:2017-25. [PMID: 32773463 DOI: 10.14309/ajg.0000000000000762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
72 Cohen-Mekelburg S, Waljee AK, Kenney BC, Tapper EB. Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2340-2348.e3. [PMID: 31927111 DOI: 10.1016/j.cgh.2019.12.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
73 Tapper EB. Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis. Hepatology 2019;70:403-9. [PMID: 30703852 DOI: 10.1002/hep.30533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
74 Powell EE, Skoien R, Rahman T, Clark PJ, O'Beirne J, Hartel G, Stuart KA, McPhail SM, Gupta R, Boyd P, Valery PC. Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians. EClinicalMedicine 2019;11:44-53. [PMID: 31317132 DOI: 10.1016/j.eclinm.2019.05.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
75 Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319-31. [DOI: 10.1111/apt.13858] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 14.7] [Reference Citation Analysis]
76 Louissaint J, Grzyb K, Bashaw L, Mohammad RA, Parikh ND, Tapper EB. An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis. Am J Gastroenterol 2022;117:491-4. [PMID: 35020619 DOI: 10.14309/ajg.0000000000001608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Carbonneau M, Davyduke T, Congly SE, Ma MM, Newnham K, Den Heyer V, Tandon P, Abraldes JG. Impact of specialized multidisciplinary care on cirrhosis outcomes and acute care utilization. CanLivJ 2021;4:38-50. [DOI: 10.3138/canlivj-2020-0017] [Reference Citation Analysis]
78 Gaspar R, Rodrigues S, Silva M, Costa-Moreira P, Morais R, Andrade P, Cardoso H, Albuquerque A, Liberal R, Macedo G. Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis. Dig Liver Dis 2019;51:1423-9. [PMID: 31113738 DOI: 10.1016/j.dld.2019.03.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
79 Kruger AJ, Aberra F, Black SM, Hinton A, Hanje J, Conteh LF, Michaels AJ, Krishna SG, Mumtaz K. A validated risk model for prediction of early readmission in patients with hepatic encephalopathy. Annals of Hepatology 2019;18:310-7. [DOI: 10.1016/j.aohep.2018.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
80 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
81 Elsaid MI, John T, Li Y, Pentakota SR, Rustgi VK. The Health Care Burden of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:263-75. [DOI: 10.1016/j.cld.2020.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H, Osman M, Siddiqui MS, Fuchs M, Puri P, Sikaroodi M, Gillevet PM. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology 2019;70:1690-703. [PMID: 31038755 DOI: 10.1002/hep.30690] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 35.0] [Reference Citation Analysis]
83 Qu Y, Li T, Lin C, Liu F, Wu S, Wang L, Ye Q. Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations. Clin Res Hepatol Gastroenterol 2021;45:101729. [PMID: 34091081 DOI: 10.1016/j.clinre.2021.101729] [Reference Citation Analysis]
84 Gajendran M, Umapathy C, Perisetti A, Loganathan P, Dwivedi A, Alvarado LA, Zuckerman MJ, Goyal H, Elhanafi S. Nationwide analysis of incidence and predictors of 30-day readmissions in patients with decompensated cirrhosis. Frontline Gastroenterol 2022;13:295-302. [DOI: 10.1136/flgastro-2021-101850] [Reference Citation Analysis]
85 Bloom P, Wang T, Marx M, Tagerman M, Green B, Arvind A, Ha J, Bloom J, Richter JM. A Smartphone App to Manage Cirrhotic Ascites Among Outpatients: Feasibility Study. JMIR Med Inform 2020;8:e17770. [PMID: 32876581 DOI: 10.2196/17770] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
86 Tansel A, Kramer J, Feng H, El-serag HB, Kanwal F. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci 2019;64:1470-7. [DOI: 10.1007/s10620-019-5459-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Bloom PP, Tapper EB. The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. J Clin Med 2020;9:E3620. [PMID: 33182743 DOI: 10.3390/jcm9113620] [Reference Citation Analysis]
88 Rosenblatt R, Yeh J, Gaglio PJ. Long-Term Management: Modern Measures to Prevent Readmission in Patients with Hepatic Encephalopathy. Clin Liver Dis 2020;24:277-90. [PMID: 32245533 DOI: 10.1016/j.cld.2020.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
89 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Khan A, Maheshwari S, Gupta K, Naseem K, Chowdry M, Singh S. Rate, reasons, predictors, and burden of readmissions after transjugular intrahepatic portosystemic shunt placement. J Gastroenterol Hepatol 2021;36:775-81. [PMID: 32710679 DOI: 10.1111/jgh.15194] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Han X, Luo Z, Wang W, Zheng P, Li T, Mei Z, Wang J. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Front Pharmacol 2021;12:696065. [PMID: 34690751 DOI: 10.3389/fphar.2021.696065] [Reference Citation Analysis]
92 Sack J, Hashemi N. Smartphone-Based Remote Health Monitoring-Implications for Healthcare Delivery in Patients with Cirrhosis. J Gen Intern Med 2019;34:2726-7. [PMID: 31090028 DOI: 10.1007/s11606-019-05046-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Shen NT, Schneider Y, Congly SE, Rosenblatt RE, Namn Y, Fortune BE, Jesudian A, Brown RS. Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. Clin Gastroenterol Hepatol. 2018;16:1503-1510.e3. [PMID: 29609068 DOI: 10.1016/j.cgh.2018.03.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
94 Duong NK, Shrestha S, Park D, Shahab O, Fagan A, Malpaya Z, Gallagher ML, Morris A, Davis BC, Bajaj JS. Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis. Am J Gastroenterol 2021. [PMID: 34738545 DOI: 10.14309/ajg.0000000000001550] [Reference Citation Analysis]
95 Carbonneau M, Eboreime EA, Hyde A, Campbell-scherer D, Faris P, Gramlich L, Tsuyuki RT, Congly SE, Shaheen AA, Sadler M, Zeman M, Spiers J, Abraldes JG, Sugars B, Sia W, Green L, Abdellatif D, Schaefer JP, Selvarajah V, Marr K, Ryan D, Westra Y, Bakshi N, Varghese JC, Tandon P. The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial. BMC Health Serv Res 2020;20. [DOI: 10.1186/s12913-020-05427-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Louissaint J, Lok AS, Fortune BE, Tapper EB. Acceptance and use of a smartphone application in cirrhosis. Liver Int 2020;40:1556-63. [DOI: 10.1111/liv.14494] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
97 Cullaro G, Rubin JB, Fortune BE, Crawford CV, Verna EC, Hsu CY, Liu KD, Brown RS, Lai JC, Rosenblatt R. Association Between Kidney Dysfunction Types and Mortality Among Hospitalized Patients with Cirrhosis. Dig Dis Sci 2021. [PMID: 34292470 DOI: 10.1007/s10620-021-07159-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Stoll AM, Guido M, Pence A, Gentene AJ. Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy. Ann Pharmacother 2022;:10600280221100537. [PMID: 35658580 DOI: 10.1177/10600280221100537] [Reference Citation Analysis]
99 Okafor PN, Nnadi AK, Okoli O, Huang AE, Nwaiwu O. Same- vs Different-Hospital Readmissions in Patients With Cirrhosis After Hospital Discharge. Am J Gastroenterol. 2019;114:464-471. [PMID: 30676364 DOI: 10.14309/ajg.0000000000000050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
100 Hu XP, Gao J. International normalized ratio and Model for End-stage Liver Disease score predict short-term outcome in cirrhotic patients after the resolution of hepatic encephalopathy. World J Gastroenterol 2019; 25(26): 3426-3437 [PMID: 31341366 DOI: 10.3748/wjg.v25.i26.3426] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Caughron H, Parikh D, Allison Z, Deuse T, Mahadevan VS. Outcomes of transcatheter aortic valve replacement in end stage liver and renal disease. Catheter Cardiovasc Interv 2021;98:159-67. [PMID: 33594809 DOI: 10.1002/ccd.29559] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Lavekar A, Raje D, Sadar A, Manohar T, Manjari KS, Satyanarayana PT. Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver. Euroasian J Hepatogastroenterol 2019;9:71-7. [PMID: 32117694 DOI: 10.5005/jp-journals-10018-1302] [Reference Citation Analysis]
103 Mah JM, Dewit Y, Groome P, Djerboua M, Booth CM, Flemming JA. Early hospital readmission and survival in patients with cirrhosis: A population-based study. CanLivJ 2019;2:109-20. [DOI: 10.3138/canlivj.2018-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
104 Kröner PT, Aby ES, Wijarnpreecha K, Palmer W. Wilson disease-related cirrhosis is associated with increased odds of hemolytic anemia. J Evid Based Med 2022;15:15-8. [PMID: 35416435 DOI: 10.1111/jebm.12463] [Reference Citation Analysis]
105 Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas HE, Lai J, Thacker LR, Reddy KR. Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clin Gastroenterol Hepatol 2017; 15: 565-574. e4. [PMID: 27720916 DOI: 10.1016/j.cgh.2016.09.157] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 11.7] [Reference Citation Analysis]
106 Bajaj JS, Acharya C, Sikaroodi M, Gillevet PM, Thacker LR. Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. GastroHep 2020;2:79-86. [PMID: 33071650 DOI: 10.1002/ygh2.390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
107 Adejumo AC, Cholankeril G, Iqbal U, Yoo ER, Boursiquot BC, Concepcion WC, Kim D, Ahmed A. Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. Dig Dis Sci 2020;65:990-1002. [PMID: 31372912 DOI: 10.1007/s10620-019-05759-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
108 Atteberry P, Biederman B, Jesudian A, Lucero C, Brown RS Jr, Verna E, Sundaram V, Fortune B, Rosenblatt R. Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. J Gastroenterol Hepatol 2021. [PMID: 34293211 DOI: 10.1111/jgh.15633] [Reference Citation Analysis]
109 Patel H, Balar B, Irigela M, Vootla V, Chandrala C, Hashmi H, Abdulsamad M, Makker J. Risk Factors for Liver Cirrhosis-Related Readmissions in the Largest Ethnic Minority in United States. Gastroenterology Res 2020;13:11-8. [PMID: 32095168 DOI: 10.14740/gr1227] [Reference Citation Analysis]
110 Dai J, Zhao J, Du Y, McNeil EB, Chongsuvivatwong V. Biomarkers and sociodemographic factors predicting one-year readmission among liver cirrhosis patients. Ther Clin Risk Manag 2019;15:979-89. [PMID: 31496713 DOI: 10.2147/TCRM.S203883] [Reference Citation Analysis]
111 Sarwar A, Weinstein JL, Novack V, Chakrala N, Tapper EB, Malik R, Ahmed M. Causes and Rates of 30-Day Readmissions After Transjugular Intrahepatic Portosystemic Shunts. AJR Am J Roentgenol 2020;215:235-41. [PMID: 32374665 DOI: 10.2214/AJR.19.21732] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Bajaj JS, Fan S, Thacker LR, Fagan A, Gavis E, White MB, Heuman DM, Fuchs M, Fiehn O. Serum and urinary metabolomics and outcomes in cirrhosis. PLoS One 2019;14:e0223061. [PMID: 31560724 DOI: 10.1371/journal.pone.0223061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
113 Frenette CT, Levy C, Saab S. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door. Dig Dis Sci 2021. [PMID: 34169435 DOI: 10.1007/s10620-021-07075-2] [Reference Citation Analysis]
114 Acharya C, Bajaj JS. Hepatic Encephalopathy and Liver Transplantation: The Past, Present, and Future Toward Equitable Access. Liver Transpl 2021. [PMID: 34018659 DOI: 10.1002/lt.26099] [Reference Citation Analysis]
115 Kichloo A, El-Amir Z, Dahiya DS, Wani F, Singh J, Solanki D, Edigin E, Eseaton P, Mehboob A, Shaka H. Trends of alcoholic liver cirrhosis readmissions from 2010 to 2018: Rates and healthcare burden associated with readmissions. World J Hepatol 2021; 13(12): 2128-2136 [DOI: 10.4254/wjh.v13.i12.2128] [Reference Citation Analysis]
116 Sempokuya T, Zhang G, Nakagawa K. Temporal trends of cirrhosis associated conditions. World J Hepatol 2019; 11(1): 74-85 [PMID: 30705720 DOI: 10.4254/wjh.v11.i1.74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
117 Choudhuri AH, Khurana P, Biswas PS, Uppal R. Epidemiology and risk factors for multidrug-resistant bacteria in critically ill patients with liver disease. Saudi J Anaesth 2018;12:389-94. [PMID: 30100836 DOI: 10.4103/sja.SJA_749_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Adejumo AC, Kim D, Iqbal U, Yoo ER, Boursiquot BC, Cholankeril G, Wong RJ, Kwo PY, Ahmed A. Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. J Palliat Med 2020;23:97-106. [PMID: 31397615 DOI: 10.1089/jpm.2019.0100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
119 Tapper EB, Parikh ND, Green PK, Berry K, Waljee AK, Moon AM, Ioannou GN. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. Clin Gastroenterol Hepatol 2020;18:1197-1206.e7. [PMID: 31589975 DOI: 10.1016/j.cgh.2019.09.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
120 Williams S, Louissaint J, Nikirk S, Bajaj JS, Tapper EB. Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. United European Gastroenterol J 2021;9:193-202. [PMID: 33226300 DOI: 10.1177/2050640620975224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]